Here's Why Viatris (VTRS) is a Strong Value StockZacks Investment Research · 5 days ago
Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of PresbyopiaPRNewsWire · Oct 16, 2026
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRXBusiness Wire · Oct 12, 2026
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain PortfolioZacks Investment Research · Oct 9, 2026
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)Newsfile Corp · Oct 8, 2026
Why Pacira BioSciences Skyrocketed TodayFool - Investing News · Oct 8, 2026Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs).
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | $0.60 | $0.69 | Beat |
| May 7, 2026 | $0.50 | $0.59 | Beat |
| Feb 26, 2026 | $0.53 | $0.57 | Beat |
| Nov 6, 2025 | $0.62 | $0.67 | Beat |
| Aug 7, 2025 | $0.56 | $0.62 | Beat |
| May 8, 2025 | $0.49 | $0.50 | Beat |